While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor exec...
Moderna has the clinical lead, while BioNTech has the deeper war chest. See which cancer stock offers the stronger long-term setup as mRNA oncology enters a new phase.
Moderna (NASDAQ:MRNA) executives emphasized the company’s evolution beyond COVID-19 vaccines during a discussion with Bernstein, highlighting its mRNA platform, personalized cancer vaccine program intismeran, rare-disease pipeline and plans to expand therapeutics development.
Chief Executive Office
Moderna's story is changing fast, but the stock is already pricing in a lot. See what the Phase 3 cancer result really proves, what could come next, and where the biggest risk still sits.
What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 9.4% in the afternoon session after positive Phase 3 INTerpath-001 trial results ...
One company is growing a commercial drug business with limited margin for error on the path to profitability. The other has a platform that proved itself at global scale and keeps finding new diseases to target.
What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 7.1% in the afternoon session after the company presented at the Morgan Stanley G...
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cord...
